Vivani Medical, Inc. (VANI) Balance Sheet

The downward trend in total assets suggests that the company is consuming its capital base at a rate that outpaces its ability to replenish it through non-dilutive means. Investors should monitor whether this trajectory forces a pivot toward more aggressive financing strategies, as the current asset base provides a shrinking buffer for future R&D requirements.

The current ratio of 2.71 as of 2025Q4, while appearing superficially adequate, masks the reality that the company's primary asset is cash which is being rapidly exhausted. This liquidity profile suggests that the company may face significant pressure to secure additional funding within the next few quarters to maintain its current clinical trial momentum.

While the debt level has remained relatively stable, the high debt-to-equity ratio in periods of low equity valuation highlights the company's reliance on external capital to sustain its research-heavy business model. This leverage structure may limit financial flexibility and increase the risk of covenant breaches or further dilution if the company fails to achieve key clinical milestones.

The erosion of equity highlights the fundamental challenge of a pre-revenue medical device firm where shareholder value is primarily supported by capital raises rather than operational performance. Investors should be wary of the potential for continued dilution, as the company must likely issue additional shares to bridge the gap created by its significant accumulated deficit.